Company: GHRS
Filing Date: 2025-02-27
Form Type: 20-F
Source: 0001140361-25-006175
Chunk: 92

Company: GH Research PLC
Filing Date: 2025-02-27
Form: 20-F
Item: Item 6
Chunk 92
---
 where he studied Biochemistry and Microbiology. He has a M.Phil. and Ph.D. from the University of Cambridge where he was also a post-doctoral research fellow. Currently, he is an active investor in biomedical companies, he has a board position at Forward Pharma A/S, Cycle Pharma and ASP Isotopes. He is also the Chairman of the Scottish Life Sciences Association and serves on the Board of Governors of Merchiston Castle School in Edinburgh and the International School in Shenzhen in the Peoples Republic of China. We believe that Dr. Moore is qualified to serve on our Board of Directors because of his experience, attributes and skills, including his extensive pharmaceutical and executive experience.
B.
Compensation
 
Compensation of Directors and Executive Officers
 
For the year ended December 31, 2024, the aggregate compensation paid to the members of our Board of Directors and our executive officers for services in all capacities, including retirement and similar benefits, was $3.4 million.
 
During the year ended December 31, 2024, GH Research PLC granted options to purchase an aggregate of 1,043,120 ordinary shares to directors and executive officers. 60,000 of these share options were granted to a number of executive officers which vest 25% on the first anniversary of the date of grant, and thereafter in equal installments on a monthly basis over the subsequent three years and are subject to a two-year service condition. The contractual term (expiration) of these share options is eight years from the grant date with a weighted-average exercise price of $6.84. 33,120 of these share options were granted to members of our Board of Directors which were fully vested on the date of grant and are subject to a two-year service condition. The contractual term (expiration) of these share options is seven years from the grant date with a weighted-average exercise price of $0.025. 950,000 of these share options were granted to members of our Board of Directors and executive officers which vest 25% on the first anniversary of the date of grant, and thereafter in equal installments on a monthly basis over the subsequent three years. The contractual term (expiration) of these share options is seven years from the grant date with a weighted-average exercise price of $0.025.
 

  Table of Contents
Equity Incentive Plans
 
Share Option Plan
 
We have adopted a share option plan (referred to herein as the Share Option Plan), under which grants of options are made to eligible participants. The